No price exists for CagriSema because no approved CagriSema product exists. It is an investigational once-weekly combination of cagrilintide, a long-acting amylin analog, with semaglutide, a GLP-1 receptor agonist, and until a regulator authorizes a specific product at a specific dose there is no list price, no National Drug Code, and nothing for a pharmacy benefit manager to negotiate against. What can be described honestly is the category it would enter, where published list prices for branded weekly incretin medicines run above a thousand dollars a month and coverage, not price, is the harder variable for the patient.
CagriSema is an investigational cagrilintide and semaglutide combination with no FDA approval, no National Drug Code, and therefore no United States price, while its nearest approved branded competitor is listed by its manufacturer at roughly $1,350 for a one-month package.
The absence of a price is a legal fact, not an oversight or a withheld secret. A prescription medicine in the United States cannot be marketed, assigned a National Drug Code, listed in a pricing compendium, or placed on a formulary until the Food and Drug Administration approves a specific product at specific strengths for a specific population, so an investigational product in review has nothing to be sold as and therefore nothing to be priced at.
CagriSema has completed large phase 3 obesity trials but carries no National Drug Code, no compendium listing, and no formulary placement, because United States pricing legally begins only at FDA approval of a specific product at a specific strength.
The nearest relatives already on the market are the only honest proxy for what a future combination product in this class would cost. Branded once-weekly injectables approved for chronic weight management in the United States carry published list prices above a thousand dollars a month, yet very few patients are billed that figure. The distance between the published number and the paid number is where nearly all of the real economics in this category sit.
| Cost dimension | Branded list channel | Manufacturer cash-pay channel |
|---|---|---|
| Published monthly figure | About $1,350 per one-month package | A few hundred dollars per month |
| Annual figure before discounts | About $17,500 | Varies by program terms |
| Scaling with dose | Flat across starting and maintenance doses | Flat across doses |
| Insurance claim | Filed through the plan | Forgone by the patient |
The leading branded weekly injectable for chronic weight management is listed by its own manufacturer at about $1,350 for a one-month package, roughly $17,500 a year before any discount, while manufacturer-run cash-pay channels have offered the same molecules in the range of a few hundred dollars a month.
Three different numbers get called the price of a drug, and confusing them is the single largest source of sticker shock in this category. Separating them explains why two people holding the same prescription at the same pharmacy counter can be charged amounts that differ by an order of magnitude.
A drug in this class carries three separate prices, the manufacturer's published list price, the post-rebate net price the plan pays, and the patient cost share set by plan design, and a patient in the deductible phase is billed against the list figure while the plan behind them pays materially less.
The common assumption is that an approved obesity medicine carries some baseline entitlement to coverage. It does not: the federal essential health benefits requirement reaches only individual and small group coverage, so the large group and self-funded employer plans that cover most workers are free to exclude the category outright, and no federal rule obliges any plan to cover weight-management drugs specifically.
No federal rule requires large group or self-funded employer plans to cover weight-management drugs, and the most recent national employer survey found coverage of incretin obesity medicines at 16 percent of firms with 200 to 999 workers, 30 percent at 1,000 to 4,999 workers, and 43 percent at 5,000 or more.
The barrier in Medicare was written into law rather than decided plan by plan. The statute establishing the outpatient drug benefit lists categories a plan may exclude, and agents used for weight loss appear on that list, a provision dating from an era when the available weight-loss drugs were viewed as cosmetic and in some cases unsafe. What has changed sits at the margins rather than at the statute.
Medicare Part D is barred by statute from covering agents used for weight loss, so access has historically depended on a separate approved indication, and the time-limited Medicare GLP-1 Bridge demonstration began July 1, 2026 and runs through December 31, 2027 offering eligible beneficiaries certain GLP-1 medicines at a flat $50 a month.
Medicaid is the most geographically uneven part of this picture. Once a manufacturer signs the federal rebate agreement states must generally cover its products, but weight-loss agents fall under the same optional-exclusion category that applies in Medicare, which hands the decision back to each state and produces a patchwork rather than a policy.
Weight-loss agents fall under the same optional-exclusion category in Medicaid as in Medicare, so only a minority of state programs have covered incretin obesity medicines, and several states have added coverage and then scaled it back after per-member spending climbed faster than projected.
Coverage on paper and a filled prescription are two different things. Even a plan that covers the category rarely lets a prescription through unexamined, and the gates are built around the labeled population rather than around clinical judgment. The rule that surprises patients most is not the first approval but the renewal.
Prior authorization in this class has centered on a body mass index at or above 30, or at or above 27 with a documented weight-related condition, with continued coverage commonly conditioned on documented weight loss of about 5 percent by a checkpoint several months into therapy.
For a patient facing a hard exclusion the documented options narrow to a short list, and they differ sharply by which payer the patient sits under. The route with the worst published track record is also the easiest one to stumble into.
Manufacturer-run direct pharmacy channels dispense the actual approved branded product at a flat self-pay price well below list, while manufacturer copay assistance cards remain unavailable to anyone enrolled in a federal program under anti-kickback rules.
Pricing pressure in this category is coming from the pipeline rather than from policy. Multiple weekly injectables, several oral agents, and a series of combination products aimed at greater weight loss or better tolerability are all advancing, and a new entrant has little room to price above the incumbents without losing formulary position. History in other therapeutic classes suggests where that pressure lands, and it is not on the patient in a deductible.
Competition in a crowded incretin pipeline historically deepens confidential rebates rather than cutting published list prices, so coverage breadth rather than sticker price determines what most patients actually pay.
Budgeting for a medicine in this class means budgeting for a chronic therapy rather than a course of treatment. Obesity is managed, not cured, by these agents, and that single fact reframes every figure attached to them.
Agents in this class manage obesity rather than cure it, and trial evidence consistently shows a substantial portion of lost weight returns within roughly a year of discontinuation, so the realistic planning horizon is years of continuous therapy plus monitoring visits and laboratory work.
Educational use only. This article describes what the published scientific and clinical literature reports about CagriSema. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
